Citation
Romo, Matthew L.; Edwards, Jessie K.; Semeere, Aggrey S.; Musick, Beverly S.; Urassa, Mark; Odhiambo, Francesca; Diero, Lameck; Kasozi, Charles; Murenzi, Gad; & Lelo, Patricia, et al. (2022). Viral Load Status before Switching to Dolutegravir-Containing Antiretroviral Therapy and Associations with Human Immunodeficiency Virus Treatment Outcomes in Sub-Saharan Africa. Clinical Infectious Diseases, 75(4), 630-637. PMCID: PMC9464076Abstract
BACKGROUND: Dolutegravir is being rolled out globally as part of preferred antiretroviral therapy (ART) regimens, including among treatment-experienced patients. The role of viral load (VL) testing before switching patients already on ART to a dolutegravir-containing regimen is less clear in real-world settings.METHODS: We included patients from the International epidemiology Databases to Evaluate AIDS consortium who switched from a nevirapine- or efavirenz-containing regimen to one with dolutegravir. We used multivariable cause-specific hazards regression to estimate the association of the most recent VL test in the 12 months before switching with subsequent outcomes.
RESULTS: We included 36 393 patients at 37 sites in 5 countries (Democratic Republic of the Congo, Kenya, Rwanda, Tanzania, Uganda) who switched to dolutegravir from July 2017 through February 2020, with a median follow-up of approximately 11 months. Compared with those who switched with a VL <200 copies/mL, patients without a recent VL test or with a preswitch VL
URL
http://dx.doi.org/10.1093/cid/ciab1006Reference Type
Journal ArticleYear Published
2022Journal Title
Clinical Infectious DiseasesAuthor(s)
Romo, Matthew L.Edwards, Jessie K.
Semeere, Aggrey S.
Musick, Beverly S.
Urassa, Mark
Odhiambo, Francesca
Diero, Lameck
Kasozi, Charles
Murenzi, Gad
Lelo, Patricia
Wyka, Katarzyna
Kelvin, Elizabeth A.
Sohn, Annette H.
Wools-Kaloustian, Kara K.
Nash, Denis